A central event in the development of an adaptive immune response is the activation of CD4
ϩ T cells. In vaccine development, strategies that increase their activation are therefore attractive. CD4 ϩ T cells become activated when they recognize peptides presented on MHC class II molecules. Thus, an approach to augment their activation has been to increase the number of MHC-peptide complexes on the APC (1) (2) (3) (4) (5) . This has traditionally been accomplished by complexing antigenic proteins to Ab that are specific for surface markers on APC. Such targeting of Ag to APC has been shown to increase presentation and T cell activation (1) (2) (3) (4) (5) . However, large Ag-Ab conjugates may have disadvantages, such as reduced tissue penetration, short serum t 1/2 , batch to batch variability, and a low number of different Ag that can be conjugated to a single Ab.
New strategies have therefore been developed that are based on the finding that Ig are themselves processed intracellularly, so that Ig-derived peptides are presented on MHC class II molecules (6 -9) . Accordingly, various T cell epitopes have been introduced into the complementarity-determining region (CDR) 4 2 and 3 of Ab, which is part of the Ag binding site (10, 11) . A major drawback of this strategy is loss of Ab specificity. Circumventing this problem, Baier et al. (12) fused T cell epitopes to the C termini of IgD-and MHC class II-specific Fabs. The T cell activation potential of these molecules, however, was lower than that of Ab-Ag complexes (2) (3) (4) . The reduction could be due to the fact that Fabs do not allow for bivalent binding and cross-linking of target molecules. Also, peptides tailing an Ab fragment may be prone to degradation (13) .
We have chosen to make rAb that have antigenic peptides integrated into their C regions in such a way that they do not disrupt the Ig structure. In addition, these Ab have been equipped with V regions specific for APC. When the rAb are internalized and degraded by the APC, the T cell epitopes can be loaded onto MHC molecules and presented to T cells. In this study, we introduce the term Troybodies for such Ab, because their effect is comparable to that of the Trojan horse: when they enter a cell (the city of Troy) by receptor-mediated endocytosis (a gate in the city wall), their T cell epitopes (soldiers) are released. We have previously made Troybodies with specificity for IgD. When compared with a peptide-containing Ab with irrelevant specificity, the IgD-specific Troybodies were far more efficient at priming B cells for T cell activation (14) .
Previous studies have demonstrated that targeting of conventional Ag-Ab complexes to MHC class II has a positive effect on activation of specific CD4 ϩ T cells (2, 3) . In the present work, we describe the construction of MHC class II-specific Troybodies with either of four different model T cell epitopes embedded in their C regions. We show that targeting to APC by use of these Ab results in enhanced Ag presentation and T cell activation in vitro as well as in vivo. The current class II-specific Troybodies have the advantage that all the different professional APC expressing MHC class II molecules may be targeted. Indeed, enhanced presentation is obtained using B cells, dendritic cells (DC), and macrophages as APC in the assays.
Materials and Methods
Mice BALB/cABom, C.B-17/lcrBom, C57BL/6JBom, C3H/HeJBom, SCID on C.B-17 background, and the 2 315 -specific TCR-transgenic mice on a C.B-17-SCID background (15) were all from M&B (Ry, Denmark). The 2 315 -specific TCR-transgenic mice on BALB/c background (16) and the 2 315 -specific TCR-transgenic mice on a Rag2 Ϫ/Ϫ BALB/c background (unpublished) were bred in our animal facility. B10.BR (express I-A k and I-E k MHC class II molecules) and B10.A(4R) (express I-A k but lack I-E molecules) mice were from Harlan (Oxon, U.K.).
Cell lines
The 14-4-4S hybridoma (17) (6) . The T cell hybridoma 3A9 specific for hen egg lysozyme (HEL) 46 -61 (20) was a gift from R. Germain (National Institutes of Health, Bethesda, MD); the T cell hybridoma DO11.10 specific for OVA 323-339 (21) was a gift from P. Marrack (University of Colorado, Denver, CO); and the hemagglutinin (HA) 110 -120-specific CD4 ϩ T cell clone, Vir-2 (22), was a gift from A. Rolink (Basel Institute for Immunology, Basel, Switzerland).
Construction of MHC class II-specific Troybodies
Introduction of T cell epitopes. The different T cell epitopes were introduced into the C H 1 domain of a human IgG3 H chain by site-specific in vitro mutagenesis, as previously described (23, 24) . The epitopes were introduced into the loop of C H 1 that corresponds to the CDR3 loop of V domains. We have previously denoted this loop L3, but it is in this study renamed L6, as it is the sixth loop in the domain when loops are counted from the amino terminus of the folded polypeptide chain. Each T cell epitope was added by replacing the 12 nt encoding the 4-aa-long loop with nucleotides encoding the epitope. Initially, four different 5 iodo-4 hydroxy-3 nitrophenacetyl (NIP)-specific Ab were made (Table I): L6-2   315 contain the 91-101 epitope from the 2 315 Ig L chain (23) , whereas the L6-HA, L6-HEL, and L6-OVA Ab contain the 110-120 HA (25) , the 46-61 HEL (26) , and the 323-339 OVA (27) T cell epitopes, respectively (24) . These nontargeting Ab with peptide are denoted peptide Ab. Cloning of V region genes. V region genes providing specificity for MHC class II were cloned by a procedure described previously (28) . The complete rearranged V H and V L genes were cloned from the 14-4-4S hybridoma, which produces an Ab specific for the E ␣ chain (determinant Ia.7) of the I-E MHC class II molecule (17) . Briefly, the V L and V H genes were PCR amplified from cDNA using a set of upstream primers that anneal to all Ig leader sequences, in combination with a downstream primer annealing to C H 1 (28) . The PCR products were sequenced, and specific PCR primers annealing to the exact ends of the V region genes were made. These primers were designed to include restriction enzyme sites (underlined). The primer sequences were: 5Ј V L , ggt gtg cat tcc gac att gtt ctg aca cag tct cc; 3Ј V L , acg tac gtt cta ctc acg ctt gat ttc cag ctt ggt gcc; 5Ј V H , cag gtc caa ttg cag cag tct gg; 3Ј V H , gac gta cga ctc acc tga gga gac cgt gac tga ggt t. The V L and V H gene sequences have been submitted to the European Molecular Biology Laboratory GenBank, with accession numbers AF292646 and AF292391, respectively. The V region genes giving specificity for the hapten NIP have previously been described (29) . Production and purification of Troybodies. Vectors encoding complete Ab with different specificities and peptide inserts were obtained by combining V region genes (giving specificity for NIP or E ␣ ) with C region genes (with or without epitope inserts) using a strategy described previously (14) (see Table I ). The resulting pLNOH2 and pLNO vectors were transfected into NS0 cells by electroporation, and transfectants were selected and cloned in medium containing 800 g/ml G418. Ab were affinity purified from cell supernatant by use of protein L (Affitech, Oslo, Norway)-or protein G-Sepharose columns, and Ab concentrations quantified by an ELISA specific for human IgG3 (23) . The recombinant E ␣ -specific Ab are denoted: ␣E ␣ .L6-2 315 , ␣E ␣ .L6-HA, ␣E ␣ .L6-HEL, and ␣E ␣ .L6-OVA (Table I) . 
Ab and flow cytometry

Sorting of B cells, DC, and macrophages from BALB/c spleens
Resting small splenic B cells were negatively sorted on a FACSVantage (BD Biosciences), as previously described (30) . Briefly, splenocytes were stained with a mixture of biotinylated mAb with broad non-B cell specificities detected with streptavidin CyChrome. The nonfluorescent cells were selected in combination with a narrow forward light scatter (FSC)/ side light scatter lymphocyte gate. To sort DC, splenocytes were stained with FITC-labeled anti-CD11c in addition to a non-B cell mAb mixture.
CD11c
ϩ Mac1␣ Ϫ cells were positively sorted. Mac1␣ ϩ CD11c Ϫ macrophages were positively selected from splenocytes double stained with PElabeled anti-Mac1␣ and FITC-labeled anti-CD11c.
Short-term Th1 and Th2 cultures 2
315 -specific Th1-and Th2-polarized cell lines from TCR-transgenic mice were obtained as described (14) . Briefly, TCR-transgenic lymph node cells were cultured with irradiated BALB/c splenocytes and synthetic 2 315 peptide. To obtain Th1 cultures, rIL-12 and anti-IL-4 11B11 mAb were added at initiation of cultures, whereas IL-4 was added to induce differentiation into Th2 cells.
T cell proliferation and cytokine assays
Tissue culture medium used was RPMI 1640 with 10% FCS and supplements, as previously described (31) . T cell proliferation assays were performed essentially as described previously (6, 14) , with some modifications to overcome the class II-blocking activity (and thereby inhibition of T cell responses) of the class II-specific Ab. Briefly, various types of APC were incubated with titrated amounts of the different rAb and incubated for 4 h at 37°C in microtiter wells. The cultures were then washed three times before various types of responder T cells were added. When cell lines (P388D1, IIA1.6, and D2SC/1) were used as APC, the cells were treated with mitomycin C (Sigma-Aldrich, St. Louis, MO) (6). Other APC populations were irradiated with 20 Gy, except for sorted B cells, which were irradiated with only 8 Gy to maintain their APC function (32) . When T cell hybridomas were used as responders, the APC were not irradiated. The assays were put up as 200-l cultures in 96-well flat-bottom microtiter plates with the following components: 1) APC: spleen cells ( 
/well). The experiments with naive T cells from SCID or Rag
Ϫ/Ϫ mice were performed differently, in that nonirradiated TCR-transgenic SCID or Rag2 Ϫ/Ϫ spleen cells (5 ϫ 10 5 /well) were used as source of both APC and naive T cells. After 48 h, 50 l of supernatants were collected for cytokine measurements, and the cultures were pulsed for 16 -24 h with 1 Ci of 3 [H]TdR (Amersham, Little Chalfont, U.K.). The cultures were harvested, and incorporated [ 3 H]TdR was measured using a Matrix 96 beta counter or a TopCount NXT scintillation counter (Packard, Meriden, CT). IFN-␥ concentration in the supernatant was quantified by sandwich ELISA (34) . IL-4 concentration in the supernatant was measured by a similar sandwich ELISA, except for the capture mAb, which was 11B11 (ATCC), and detection Ab, which was biotinylated anti-mouse IL-4 (BD PharMingen). CTLL-2 cells were used in a bioassay to measure IL-2 concentrations in the culture supernatants (1/3 dilution) (34) . Data in Figs. 2-8 are displayed as means of triplicates, and error bars illustrate SEM.
For the fixation experiments, Troybody-pulsed or control A20 or IIA1.6 cells were fixed with 1% paraformaldehyde for 20 min and neutralized with 0.1 M glycine before setting up the proliferation assays. To inhibit intracellular processing mechanisms, chloroquine (10 M), leupeptin (5 g/ ml), brefeldin A (500 M) (all from Sigma-Aldrich), or monensin (0.67 g/ml GolgiStop; BD PharMingen) was added to the cultures, and the cells were incubated for 120 min at 37°C before fixation and addition of T cells. injections, the mice were killed by cervical dislocation, and the spleens or draining lymph nodes were removed. Irradiated (8 Gy) spleen or lymph node cells were cultured with responder T cells, as described above, but without addition of Ag.
Priming of APC in vivo
In vivo blastogenesis and expansion of T cells
BALB/c mice were reconstituted with lymph node cells and splenocytes from 2 315 -specific TCR-transgenic mice (16) . A total of 15.8 ϫ 10 6 cells was injected i.v. into each mouse (2.1 ϫ 10 6 of these cells were CD4 ϩ V␤8.2 ϩ ). On the following day, BALB/c mice were injected s.c. in the right flank region with the indicated amounts of MHC class II-specific Troybodies, nontargeting peptide Ab, or synthetic peptide. All mice received 1 ϫ 10 5 U of GM-CSF at the same site concurrently with the Ag immunization. Two mice received PBS only. After 4 days, mice were killed by cervical dislocation. Draining (inguinal) and nondraining (mesenteric) lymph nodes were isolated and prepared for flow cytometric staining. The cells were triple stained with FITC-conjugated anti-V␤8.2 (F23.1; BD PharMingen), biotinylated GB113 mAb clonotype specific for the transgenic TCR (35) , and APC-conjugated anti-CD4 (BD PharMingen). The biotinylated GB113 mAb was detected by streptavidin CyChrome. The cells were run on a FACSCalibur cytometer.
Results
Construction of MHC class II-specific Troybodies with T cell epitopes inserted into their C region
This study addresses whether class II-specific Troybodies may efficiently deliver T cell epitopes for class II presentation to CD4 ϩ T cells. To this end, Troybodies were constructed that have V regions specific for class II molecules, and various model T cell epitopes in the constant part. As model T cell epitopes, the following were used: aa residues 91-101 from the mouse 2 315 Ig L chain (33) , 323-339 OVA (27) , 110 -120 HA (25) , and 46 -61 HEL (26) . The 2 315 epitope is presented on I-E d class II molecules to CD4
ϩ T cells (6, 33) , as is the HA epitope (36) . The HEL epitope is presented on I-A k class II molecules (20) , whereas OVA is presented on I-A d (27) . These T cell epitopes have previously been introduced into C H 1 of the human ␥3 chain and expressed with hapten (NIP)-specific V regions (Table I ). More specifically, such nontargeting peptide Ab were made by genetically exchanging loop 6 (L6) of C H 1 of human IgG3 with the various T cell epitopes. L6 corresponds to the CDR3 loop in the V region and connects ␤-strands of the domain. Because V domains can accommodate large sequence variation in their CDR3 loops, the L6 loop was chosen as the site for peptide introduction. Indeed, by analogy to CDR3 (10, 11) , the L6 loop appears to accept engraftment of new peptide sequences (14, 24) .
Troybodies with MHC class II specificity were constructed by replacing the NIP-specific V regions of the four different L6 Ab (Table I) with V region genes cloned from the 14-4-4S hybridoma. The 14-4-4S hybridoma produces a mAb specific for the murine E ␣ chain (Ia.7) and binds I-E molecules of the haplotypes H- Table I ). The specificity of the Troybodies was verified by flow cytometry. Fig. 1, left peptide Ab ( Fig. 2A ). Control Ab with class II specificity, but without epitope insert (␣E ␣ .wt), did not elicit any response. ␣E ␣ .L6-2 315 was 10,000 times more efficient at stimulating T cell proliferation than synthetic 2 315 peptide, on a molar basis (Fig.  2B ). Physical linkage of the epitope and the I-E-specific V regions seems to be required, because simultaneous addition of both L6-2 315 and ␣E ␣ .wt failed to elicit an increased T cell activation (data not shown).
Possibly, the presence of ␣E ␣ .L6-2 315 could inhibit specific T cell activation, because they could block the same class II molecules that present the epitope to T cells. This was studied in an experiment in which the washing procedure performed before T cell addition was omitted. The results in Fig. 2C show that the presentation efficiency was dramatically reduced for high, but not low, Ab concentrations. This indicates that high amounts of ␣E ␣ .L6-2 315 in the supernatant bind and block MHC class II molecules on APC, thereby reducing T cell stimulation. ␣E ␣ .L6-2 315 rapidly bound APC, as cultures could be washed already after 15-min incubation without much loss of presentation. As would be expected, no such blocking effect was observed when nontargeting (NIP-specific) Ab was used (data not shown).
Class II-specific Troybodies with a variety of model T cell epitopes are efficiently presented
Troybodies with the same I-E class II specificity, but with other model T cell epitopes embedded in loop 6 of their C H 1 domain, were tested for their ability to activate specific T cells. The epitopes were 110 -120 HA, 46 -61 HEL, and 323-339 OVA.
The in vitro antigenicity of the HA-expressing Ab was assessed in dose response T cell activation assays with cocultures of BALB/c spleen cells as APC and HA-specific I-E d -restricted Vir-2 cells as responder CD4
ϩ T cells (Fig. 3A) . The results show that the HA epitope was presented at least 100-fold more efficient when added as part of a ␣E ␣ .L6-HA compared with its nontargeted counterpart. Moreover, when compared with synthetic peptide, ␣E ␣ .L6-HA was ϳ100,000 times more efficient on a molar basis.
In Fig. 3B , we compared nontargeted L6-OVA and targeted ␣E ␣ .L6-OVA in an in vitro T cell proliferation assay with BALB/c spleen cells as APC and OVA-specific I-A d -restricted DO11.10 T cell hybridoma cells as responders. Based on molar ratios, ␣E ␣ .L6-OVA was at least 1,000 times more effective than L6-OVA and 10,000 times more effective than complete OVA.
To investigate the Troybody with the HEL epitope, spleen cells from B10.BR mice were used as APC, because they express the targeted I-E k molecule as well as the I-A k molecules necessary for presentation of the HEL epitope. ␣E ␣ .L6-HEL was 10,000 times more efficient than L6-HEL and synthetic HEL peptide on a molar basis. As would be expected, when APC derived from B10.A(4R) mice, which express I-A k but no I-E molecules, were used, the targeting effect was not observed (data not shown). This demonstrates that the target molecule of the Troybody has to be expressed on the surface of APC for enhanced presentation to occur.
Efficient presentation of epitopes located in Troybodies is dependent on intracellular processing
Protein Ag, including Ab, must be partially degraded intracellularly before fragments can be loaded onto class II molecules for transport to the APC surface. To verify that the epitopes inserted in the class II-specific Troybodies needed processing before T cell recognition, A20 (H-2 d ) B lymphoma cells were incubated for various lengths of time with ␣E ␣ .L6-2 315 , followed by fixation with paraformaldehyde and addition of specific T cells. As shown in Fig. 4A , A20 cells fixed after 120-min incubation at 37°C with ␣E ␣ .L6-2 315 induced T cell stimulation, while cells incubated for 30 or 60 min were only weakly stimulatory. Furthermore, when chloroquine, an agent known to inhibit acidification of lysosomes, was added during the 120-min incubation period before fixation, the APC did not acquire T cell activation capacity. Interestingly, leupeptin, a cysteine protease inhibitor, was only weakly inhibitory. This suggests that other proteases, some of which may not be inhibited by leupeptin, are active in the intracellular processing liberating the 2 315 epitope. Fixation of the APC did not interfere with the presentation of the 2 315 synthetic peptide, consistent with the notion that short peptides can bind directly to class II molecules without intracellular processing (data not shown). Similar results were obtained when A20 or IIA1.6 cells were pulsed with ␣E ␣ .L6-OVA or ␣E ␣ .L6-HA, except that in these cases, leupeptin had a much more pronounced effect (Fig. 4, B and C) . Thus, not completely overlapping sets of proteases may be active in the release of the three different T cell epitopes.
Brefeldin A is known to inhibit egress of newly synthesized class II molecules by fusing the endoplasmic reticulum and Golgi. Brefeldin A inhibited T cell stimulation induced by ␣E ␣ .L6-OVA (Fig. 4B) and ␣E ␣ .L6-HA (Fig. 4C) , which indicates that newly synthesized class II molecules are required for effective class II presentation of Troybodies to CD4 ϩ T cells. Monensin is another agent known to inhibit vesicular transport, which results in accumulation of newly synthesized proteins in the Golgi complex. Monensin blocked presentation of ␣E ␣ .L6-HA (Fig. 4C) .
Notably, the OVA epitope is presented by I-A d , another class II molecule than the target for ␣E ␣ .L6-OVA (I-E d ) (Fig. 3B) . Thus, the liberated T cell epitope is efficiently presented by another isotype of class II molecules than the one initially bound by ␣E ␣ . L6-OVA on the surface of the APC. Similarly, the HEL epitope is presented by I-A k molecules (Fig. 3C) , whereas ␣E ␣ .L6-HEL is targeted to I-E molecules (I-E k ). Nevertheless, the HEL epitope is efficiently presented, indicating that binding of ␣E ␣ .L6-HEL to I-E k results in processing and presentation by another class II molecule, I-A k . Taken together, these findings are consistent with a requirement for conventional Ag processing of Troybodies.
B cells, DC, and macrophages efficiently present epitopes delivered by class II-specific Troybodies
Previous results have shown that IgD-specific Troybodies efficiently prime B cells (14, 24) . The present class II-specific Troybodies should target other professional APC as well, such as DC and macrophages.
To define the role of the different APC involved, we repeated the experiments with various in vitro cell lines as APC. In all experiments, pure day 10 or day 20 (stimulated twice) Th2 cells were used as responder cells. According to the dose response curve, B cell lymphoma IIA1.6 (Fig. 5A) was at least 1,000 times more efficient at inducing T cell proliferation when Ag was delivered by ␣E ␣ .L6-2 315 than when delivered by the nontargeting L6-2 315 peptide Ab. When the immature DC line D2SC/1 (Fig. 5B ) and the macrophage cell line P338D1 (Fig. 5C) were used, the targeting effect was less pronounced (100 times). Whereas the cultured cell lines are pure, they have a disadvantage, in that they may differ from their in vivo counterparts. In accordance with this, both the immature DC line and the macrophage cell line express only low levels of MHC class II (data not shown) and, consequently, should be poor APC compared with cells sorted directly from the spleen. We therefore repeated the experiments with ex vivo cells purified by cell sorting from BALB/c spleens. Negatively selected, small B cells (Fig. 5D) , positively selected DC (Fig. 5E) , and positively selected macrophages (Fig. 5F ) were Ͼ1000 times more efficient at presenting T cell epitopes delivered by ␣E ␣ .L6-2 315 , compared with T cell epitopes located in nontargeting peptide Ab. Similar results were observed when measuring IL-4 in the culture supernatants (data not shown).
Class II-specific Troybodies enhance activation of naive T cells
Consistent with the results of Fig. 5 , SCID spleen non-B cell APC were found to efficiently stimulate 2 315 -specific Th2-type cells in the presence of ␣E ␣ .L6-2 315 Troybodies (data not shown). However, in this and previous experiments (Figs. 2-5) , the responder T cells were either cloned T cells, T hybridoma cells, or lymph node cells obtained from TCR-transgenic mice. Whereas the clones and hybridomas clearly were not naive, the 2 315 -specific TCR-transgenic lymph node cells used in Fig. 2 had not been deliberately activated with Ag previous to the experiments. Even so, we cannot exclude the possibility that transgenic lymph node T cells may have been activated via rearranged and expressed endogenous TCR. Thus, to test naive cells as responders, we used recombination-deficient 2 315 -specific TCR-transgenic mice on a C.B-17 SCID or BALB/c Rag2 Ϫ/Ϫ background. Nonirradiated spleen cells served as a source of both APC (macrophages and DC) and T cells. This approach has the advantage that T cells were not purified or manipulated, which increases their likelihood of being naive. The dose response curves show that ␣E ␣ .L6-2 315 was 100 -500 times more efficient than L6-2 315 at inducing proliferation (Fig. 6A ) and IL-2 production (Fig. 6B) of naive T cells. Because the splenocytes were not irradiated in these experiments (Fig. 6, A and B) , one could argue that we could be measuring proliferation of other cells than specific naive T cells. We therefore repeated the experiment with purified CD4 ϩ T cells from 2 315 -specific TCR-transgenic SCID mice as responders and irradiated B cell-deficient SCID splenocytes as APC. Consistent with the results above, strong proliferation of purified CD4 ϩ T cells was observed; MHC class IIspecific Troybodies were 1,000 -10,000 times more potent than nontargeting peptide Ab and synthetic peptide on a molar basis (Fig. 6C) .
Enhanced presentation of Ag delivered by class II-specific Troybodies in vivo
To investigate whether the class II-specific Troybodies could be delivered to splenic APC in vivo, C.B-17 or BALB/c (IgH congenic H-2 d mice) were injected i.v. with various amounts of class II-specific Troybodies, the corresponding nontargeting peptide Ab, synthetic peptides, or complete proteins. The spleens were removed after 90 min, and splenocytes were used as APC in T cell activation assays.
The dose response curves in the various systems show that the class II-specific Troybodies were at least 100 times more efficient at loading spleen APC with peptide than were the peptide Ab (Fig.  7) . Consistent results were obtained when measuring T cell activation as proliferation of responder T cells from TCR-transgenic lymph nodes (Fig. 7A) , IFN-␥ production (Fig. 7, B and C) , IL-2 production (Fig. 7D) , and when measuring proliferation of Th1 cells derived from TCR-transgenic mice (data not shown). Compared with synthetic peptides, Troybodies were Ͼ100,000 times (HA system, Fig. 7C ) and 100 -1,000 times (OVA system, Fig.  7D ) more efficient. Compared with complete protein Ag, Troybodies were Ͼ1,000 times more efficient (OVA system, Fig. 7D ). Similar results were obtained when titrated amounts of class IIspecific Troybodies (␣E ␣ .L6-HEL), nontargeting peptide mAb (L6-HEL), and synthetic HEL peptide were injected s.c. in the right flank region of C3H mice together with 1 ϫ 10 4 U of GM-CSF. The draining inguinal lymph node was taken out 24 or 72 h after injection and used as APC for HEL-specific 3A9 T hybridoma cells (data not shown). Taken together, the results demonstrate that class II-specific Troybodies have the ability to reach their APC target in vivo, after both i.v. and s.c. administration.
MHC class II-specific Troybodies injected s.c. induce clonal expansion of specific T cells
BALB/c mice were reconstituted with splenocytes and lymph node cells from 2 315 -specific TCR-transgenic mice before immunization with titrated amounts of MHC class II-specific Troybodies (␣E ␣ .L6-2 315 ), nontargeting peptide Ab (L6.2 315 ), or synthetic 2 315 peptide in combination with GM-CSF. Two mice received only PBS. The fraction of 2 315 -specific TCR-transgenic CD4 ϩ T cells among lymph node cells after reconstitution was 1-2% of total CD4 ϩ T cells (Fig. 8A, upper right contour plots) . Four days postimmunization, the fraction of TCR-transgenic CD4 ϩ T cells was increased 4-fold in mice receiving 200 g of MHC class IIspecific Troybodies (Fig. 8, A, upper left contour plots, and B, left  panel) . As would be expected, the expanded TCR-transgenic CD4 ϩ T cells had increased size (FSC), indicating blastogenesis (Fig. 8, A, lower contour plots, and B, right) . Importantly, whereas with titrated amounts of the various class II-specific Troybodies (collectively denoted ␣E ␣ .L6-epitope), the corresponding nontargeting peptide-Ab (L6-epitope), synthetic peptides, or native protein as indicated (two mice per point). After 90 min, the spleens were removed and splenocytes were irradiated (8 Gy) and used as APC in a T cell proliferation assay. A, 2 315 system: proliferation of lymph node cells from 2 315 -specific TCRtransgenic mice was assayed. B, 2 315 system: IFN-␥ production by the 2 315 -specific T cell clone (7A10B2) was assayed. C, HA system: IFN-␥ production of the HA-specific Vir-2 T cell clone was assayed. D, OVA system: IL-2 production of the DO.11.10 T cell hybridoma was assayed. ϩ T cell activation and expansion in vivo after s.c. injections when coadministrated with GM-CSF. GM-CSF alone apparently had no effects, as no responses above PBS were obtained with low concentrations of Ag. MHC class II-specific Troybodies were at least 1,000-fold more potent than synthetic peptide, whereas the difference was ϳ100-fold compared with peptide Ab (less for blastogenesis).
Discussion
Targeting of Ag to APC has been shown to be an efficient strategy for increasing Ag presentation and T cell activation. Usually, this has been achieved using complexes of complete antigenic proteins and Ab specific for APC (1) (2) (3) (4) (5) . As a further development, we have made rAb, denoted Troybodies, which have V regions specific for APC, and defined T cell epitopes as an integral part of their C region (14, 24) . We have previously shown that IgD-specific Troybodies efficiently target T cell epitopes to B cells, resulting in increased epitope presentation and T cell activation (14, 24) . However, as the amount of in vivo data in the literature is growing, it has become increasingly clear that targeting to IgD may well give heterogeneous results (4, (37) (38) (39) (40) . We have therefore engineered and tested Troybodies with specificity for a target universally expressed by professional APC, the I-E MHC class II molecule. E ␣ specificity was obtained by cloning H and L chain V regions from an anti-E ␣ (Ia.7) B cell hybridoma. The V regions were combined with C regions already containing T cell epitopes by a cloning procedure described previously (28) . In principle, the procedure should allow introduction of V region genes from any B cell hybridoma or V gene display library, and makes possible construction of Troybodies with any chosen specificity.
Four different model T cell epitopes (2 315 , HA, OVA, and HEL) were targeted to I-E on APC, and in all cases, an ϳ1000-fold increase in in vitro T cell activation was obtained when compared with nontargeted peptide Ab. The need for targeting was further demonstrated by the fact that the APC had to express the I-E class II molecule for the effect to be seen. The magnitude of the targeting effect was similar to that observed previously using Ag-Ab complexes (2, 3) and IgD-specific Troybodies (14, 24) . The targeting effect appears higher than that of IgD-or class II-specific Fabs with T cell epitopes fused to their C termini (12) . Consistent with this, we have previously observed that Fabs derived from anti-IgD Troybodies are much less efficient than complete Ab (14) . Therefore, bivalent binding or cross-linking may be crucial. Alternatively, T cell epitopes that are integrated as loops (10, 11, 24) could be treated differently by APC than those attached to the carboxyl terminus (12) .
MHC class II presentation of exogenously derived peptides usually depends on newly synthesized class II molecules (41) . In the present setting, class II molecules also serve as targets for Troybodies, and the T cell epitopes derived from the Troybodies were found to be presented on either the same (2 315 and HA peptides) or on a different (OVA and HEL peptides) isotype of the class II molecule. Internalization could occur on mature recycling MHC molecules or on newly synthesized MHC molecules that travel via the plasma membrane to the endosomal pathway (42) . However, newly synthesized class II molecules constitute only an extremely small fraction of the class II molecules in the cell membrane (42), and we therefore find it likely that most of the class II-specific Troybodies are internalized by recycling mature class II molecules. Recycling class II molecules are thought not to reach the late endosomal compartments, in which efficient Ag processing and loading onto newly synthesized MHC molecules probably occur (43) . Nevertheless, when Troybodies were internalized via I-E, the OVA and HEL peptides generated could be presented by another isotype of class II molecules (I-A). Moreover, the inhibition observed for OVA and HA presentation in the presence of brefeldin A, which blocks transport of newly synthesized class II molecules out of the endoplasmic reticulum, suggests that newly synthesized MHC molecules are needed for Troybody presentation. These findings suggest that peptides liberated from Troybodies reach the conventional compartment for class II loading. We do not know, however, where in the endosomal pathway the partial proteolytic degradation of the Troybodies takes place.
Because all professional APC express MHC class II molecules, class II-specific Troybodies have the potential to enroll all of these into the immune response. However, the different types of APC (B cells, DC, and macrophages) express different amounts of MHC molecules (44) . In addition, they are not identical with regard to other important APC qualities, such as the mechanisms for Ag uptake and the expression of costimulatory molecules (44) . We therefore used cell lines as well as ex vivo sorted B cells, DC, and macrophages to investigate the individual role of the three types of APC. Although the in vitro cell lines differed in their capability to activate T cells, ex vivo cells of the various types were remarkably similar.
When the class II-specific Troybodies were targeted to APC in vivo before isolation of splenic APC, a targeting effect of 100-to 100,000-fold was obtained compared with nontargeting peptide Ab, synthetic peptides, and complete proteins. This indicates that injected class II-specific Troybodies have sufficient stability to reach and bind their target in vivo. Furthermore, in mice adoptively transferred with specific T cells, class II-specific Troybodies injected s.c. in combination with GM-CSF induced expansion of specific T cells in draining lymph nodes. In this respect, the Troybodies were Ͼ1,000 times more potent than synthetic peptide on a molar basis. They were also more efficient than nontargeted peptide Ab, but in this case, the difference was less (ϳ100ϫ). This superior ability of Troybodies to seek their targets in vivo and deliver their cargo may reflect three important aspects of these rAb: the APC specificity of their V regions, the localization of T cell epitopes within the intact Ig structure, and their bivalent binding to target APC. While class II-specific Troybodies appear efficient, other receptors on macrophages and DC, such as those used for microbial Ag, might induce even more powerful responses, and we are currently probing such receptors for their potency as Troybody targets.
For the principle to be useful in vaccine development, some requirements have to be met. First, Ig domains must accept loading of different T cell epitopes. To date, we have introduced five different T cell epitopes (from 2 315 , OVA, HEL, HA, and p21 ras ) into the L6 position in human IgG3 (23, 24) (I. B. Rasmussen, T. F. Gregers, and I. Sandlie, unpublished observations). These epitopes vary in length from 11 to 25 aa and are part of very different secondary structure motifs within the native Ag. Whereas the 91-101 (2 315 ) epitope is found as a loop in the CDR3 region of the 2 315 L chain, the OVA epitope is mostly a ␤-strand (45), the HEL epitope has three turns and two ␤-strands (46) , and the p21 ras epitope has a ␤-strand/loop/␣-helix structure (47) . The structure of the HA epitope is unknown. Despite the differences in lengths and secondary structures, the five peptides have all been successfully introduced into the L6 loop without disturbing Ab folding and secretion. In addition to using the L6 loop, we have also loaded all 18 C domain loops of human IgG3 (M. Flobakk, I. B. Rasmussen, T. E. Michaelsen, B. Bogan, and I. Sandlie, unpublished observations) as well as three loops in the C H 1 domain of mouse IgG2b (48) with T cell epitopes. Taken together, it seems like the majority, but not all C domain loops can be used for introduction of many different T cell epitopes without severely compromising Ab folding and secretion.
A second requirement is that the inserted T cell epitopes have to be excised from their new positions by the Ag-processing machinery of the APC and presented to T cells. Degradation of Ig in APC has been studied (49) , and reduction of disulfide bridges by GILT (50) as well as proteolytic cleavage by cathepsins and other proteases (51) are likely to be important. We have compared rAb with the 2 315 epitope in different positions and found that most loops, but not all, are effective in terms of peptide presentation (23, 24, 48) (M. Flobakk, I. B. Rasmussen, T. E. Michaelsen, B. Bogan, and I. Sandlie, unpublished observations). A likely explanation is that the different flanking residues surrounding the epitopes in the various loops could determine which proteolytic enzymes get involved, and the efficiency by which they cut. In summary, it seems like some loop positions are more suitable for peptide insertion than others, mainly due to effects on folding and secretion, but to some extent also due to influence of the regions flanking the epitopes.
The Troybody technology offers flexibility that could be very useful in the field of vaccine development. First, it allows design of reagents that target T cell epitopes of choice to the desired type of APC. Second, small Ig-derived constructs, such as minibodies, can be developed. Third, the strategy should allow the introduction of many different T cell epitopes into different loops of the same Ab, so that a true multivaccine can be generated.
The discussion above focuses on the vaccine aspect of Troybodies. However, Troybodies could also be used for induction of specific T cell tolerance to prevent or ameliorate autoimmune diseases. For example, Troybodies directed to APC in the thymus could induce central T cell tolerance to defined peptides. Similarly, Troybodies directed to appropriate APC, such as certain immature DC (52) , could induce T cell anergy or regulatory, suppressive T cells.
